GSK plc

GSK plc Liabilities

The The Liabilities of GSK plc (GSK.L) as of Nov 2, 2026 is 45.16 B GBP. In the previous year, The Liabilities was 46.38 B GBP — a change of -2.62% (lower).

Liabilities

45.16 BGBP

YoY

-2.62%

Last updated:

In 2025, GSK plc's total liabilities amounted to 45.16 B GBP, a -2.62% difference from the 46.38 B GBP total liabilities in the previous year.

The GSK plc Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
54.39 B GBP
Jan 1, 2019
61.34 B GBP
Jan 1, 2020
59.62 B GBP
Jan 1, 2021
57.76 B GBP
Jan 1, 2022
50.05 B GBP
Jan 1, 2023
46.21 B GBP
Jan 1, 2024
46.38 B GBP
Jan 1, 2025
45.16 B GBP
The GSK plc Liabilities history
YEARLiabilitiesYoY
45.16 BGBP-2.62%
46.38 BGBP+0.36%
46.21 BGBP-7.67%
50.05 BGBP-13.35%
57.76 BGBP-3.12%
59.62 BGBP-2.79%
61.34 BGBP+12.76%
54.39 BGBP+2.84%
52.89 BGBP-2.27%
54.12 BGBP+21.43%
44.57 BGBP+24.79%
35.72 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing GSK plc's Liabilities

GSK plc's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GSK plc's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GSK plc's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GSK plc's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GSK plc’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GSK plc stock

The Liabilities of GSK plc is 45.16 B GBP in 2025.

The Liabilities of GSK plc changed from 46.38 B GBP to 45.16 B GBP, representing a -2.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc